Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background We report detailed results of The Physical Function Trial (PFT), one of seven Testosterone Trials (TTrials), which determined testosterone’s effects on mobility, self-reported physical function, falls, and patient global impression-of-change (PGIC) in older men with self-reported mobility limitation and walking speed<1.2 m/sec. We determined if testosterone’s effects on mobility differed according to baseline walking speed, mobility-limitation, or other participant-level factors. Methods The participants were 788 men≥65 years, with total testosterone<275 ng/dL, of which 390 men with mobility limitation and walking speed<1.2 m/sec enrolled in the PFT. Participants were assigned double-blind to 1% testosterone gel or placebo gel daily for 12-months. Primary outcome was Increase in 6-minute walk distance (6MWD) of ≥50 m; secondary outcomes included absolute increase in 6MWD, physical component of Short Form-36 (PF10), and exploratory outcomes PGIC and falls. Findings Intervention groups were similar at baseline. 6MWD improved significantly more in testosterone than in placebo group among all men in TTrials, and separately in men who were not enrolled in the PFT (treatment effect 8.9, 95% CI (2.2,15.6) p=0.01), but not in those who were enrolled in the PFT (treatment effect 4.1, 95% CI (−3.0,11.2) p=0.25). PF10 improved more in testosterone than in placebo group in all men in TTrials (treatment effect 3.1, 95% CI (1.2, 4.9), p=0.002) and separately in both men enrolled and not enrolled in the PFT (treatment effect 2.8, 95% CI (0.41, 5.2), p=0.02; and treatment effect 4.0, 95% CI (1.5, 6.5), p=0.002, respectively). Testosterone-treated men with baseline walking speed ≥1.2 m/sec experienced significantly greater improvements in 6MWD and in PF10 than placebo-treated men. Men reporting mobility limitation showed significantly more improvement in 6MWD and in PF10 than placebo-treated men. Fall frequency was similar in the two groups. Changes in 6MWD were significantly associated with changes in testosterone, free testosterone, DHT, and hemoglobin levels. Interpretation Testosterone consistently improved self-reported walking ability, modestly improved 6MWD in all men participating in the Testosterone Trials, but did not affect falls. Testosterone’s effect on mobility measures in older men with low testosterone were related to baseline gait speed and self-reported mobility limitation, and changes in testosterone and hemoglobin levels. Trial Registration ClinicalTrials.gov number,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gait speed and survival in older adults.
Studenski, S. (2011) · JAMA · doi:10.1001/jama.2010.1923 · Cited by 4,558
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationCesari, M., Kritchevsky, S. B., Penninx, B. W. H. J., Nicklas, B. J., Simonsick, E. M., Newman, A. B., Tylavsky, F. A., Brach, J. S., Satterfield, S., Bauer, D. C., et al. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53501.x · Cited by 1,192
Self-citationRedelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Self-citationSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629
Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
Self-citationDHEA in elderly women and DHEA or testosterone in elderly men.
Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054629 · Cited by 566
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544
Self-citation
Cited by
Corona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D., & Wu, F. C. (2020) · Andrology · doi:10.1111/andr.12770 · Cited by 431
Paediatric and adult-onset male hypogonadism
Salonia, A., Rastrelli, G., Hackett, G., Seminara, S. B., Huhtaniemi, I. T., Rey, R. A., Hellstrom, W. J. G., Palmert, M. R., Corona, G., Dohle, G. R., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0087-y · Cited by 286
Sarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 258
Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications
Pataky, M. W., Young, W. F., & Nair, K. S. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.033 · Cited by 207
Late‐onset hypogonadism: metabolic impact
Grossmann, M., Ng Tang Fui, M., & Cheung, A. S. (2020) · Andrology · doi:10.1111/andr.12705 · Cited by 95
Metadata
- Authors
- Bhasin, S., Ellenberg, S. S., Storer, T. W., Basaria, S., Pahor, M., Stephens-Shields, A. J., Cauley, J. A., Ensrud, K. E., Farrar, J. T., Cella, D., Matsumoto, A. M., Cunningham, G. R., Swerdloff, R. S., Wang, C., Lewis, C. E., Molitch, M. E., Barrett-Connor, E., Crandall, J. P., Hou, X., Preston, P., Cifelli, D., Snyder, P. J., & Gill, T. M.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 6
- Issue
- 11
- Pages
- 879-890
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2898216717
- Cited by
- 87
- References
- 21
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30171-2
- The paper
- Bhasin, S., Ellenberg, S. S., Storer, T. W., Basaria, S., Pahor, M., Stephens-Shields, A. J., Cauley, J. A., Ensrud, K. E., Farrar, J. T., Cella, D., Matsumoto, A. M., Cunningham, G. R., Swerdloff, R. S., Wang, C., Lewis, C. E., Molitch, M. E., Barrett-Connor, E., Crandall, J. P., Hou, X., . . . Gill, T. M. (2018). Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30171-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.